The Global Alliance for TB Drug Development on Wednesday signed a licensing agreement with Swiss drugmaker Novartis for compounds to fight tuberculosis, including indolcarboxamides, a novel drug class that targets strains that are resistant to other treatments. Under the agreement, the Global Alliance will take on research and development of the compounds.

Full Story:

Related Summaries